# Transgene

Source: https://onco.cc/companies/transgene/  
OnCo record `transgene` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Transgene uses modified viruses to make cancer immunotherapies. Its lead product is a personalised vaccine built from each patient's tumour mutations, given after surgery to stop head and neck cancer coming back.

## Summary

Transgene (Euronext Paris: TNG) designs virus-based immunotherapies for cancer. Its myvac platform produces individualised neoantigen vaccines on a modified vaccinia Ankara vector, with neoantigens selected by NEC's AI. Lead candidate TG4050 encodes up to 30 patient-specific neoantigens and is in a randomised phase 1/2 trial in resected HPV-negative head and neck squamous cell carcinoma. In September 2026 Transgene and NEC reported 100 percent three-year disease-free survival in all 16 TG4050-treated phase 1 patients versus three relapses among 16 controls (median follow-up 41 months), published in Nature Communications; phase 2 results are expected around the end of 2027. TG4070 extends myvac into adjuvant non-small cell lung cancer (phase 1); oncolytic viruses BT-001 and TG6050 follow. In November 2025 the company raised about EUR 105 million, with Institut Mérieux (via TSGH) and the Dassault Group participating, extending financial visibility to early 2028.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Strasbourg
- Type: biotech
- Website: https://www.transgene.com/
- Ticker: TNG.PA

## Notes

- Founding year not sourced.

## Sources

- Official website: https://www.transgene.com/
- Fundraising of about EUR 105 million (November 2025): https://www.transgene.com/wp-content/uploads/Transgene_PR_Results_EN.pdf
- TG4050 three-year disease-free survival and Nature Communications publication: https://www.transgene.com/wp-content/uploads/20260902_TG4050_NatCom_EN.pdf

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- trials: [A Clinical Trial Evaluating TG4050 in Head and Neck Cancer](https://onco.cc/trials/nct04183166/), [Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers](https://onco.cc/trials/nct03260023/)

---
JSON: https://onco.cc/api/v1/entities/transgene.json